{"id":55021,"date":"2023-03-21T12:05:12","date_gmt":"2023-03-21T11:05:12","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\/"},"modified":"2023-03-21T12:05:12","modified_gmt":"2023-03-21T11:05:12","slug":"new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\/","title":{"rendered":"New Data show NEUROMARK\u00ae Chronic Rhinitis Treatment Offers Significant Symptom Improvements"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<i>Results from the CLARITY Study Show the NEUROMARK\u00ae System Provides <\/i><i>Safe and Effective Treatment for Patients with Chronic Rhinitis<\/i>\n<\/p>\n<p>GALWAY, Ireland&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fneurentmedical.com%2F&amp;esheet=53364703&amp;newsitemid=20230321005145&amp;lan=en-US&amp;anchor=Neurent+Medical&amp;index=1&amp;md5=9ecd7cb675fd342fc6edd9027073fc17\" rel=\"nofollow noopener\" shape=\"rect\">Neurent Medical<\/a>, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, today announced three-month data from the CLARITY study, a prospective, single-arm, multicenter safety and efficacy study of its NEUROMARK\u00ae System for patients with chronic rhinitis. These data, published in <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2F10.1002%2Flio2.1040&amp;esheet=53364703&amp;newsitemid=20230321005145&amp;lan=en-US&amp;anchor=Laryngoscope+Investigative+Otolaryngology&amp;index=2&amp;md5=d0de9247cc68885976147c04bf15810a\" rel=\"nofollow noopener\" shape=\"rect\"><i>Laryngoscope Investigative Otolaryngology<\/i><\/a>, show that patients receiving the NEUROMARK therapy demonstrated significant improvement in rhinorrhea and nasal congestion symptoms at 3 months.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230321005145\/en\/1742539\/5\/Neurent_Medical_Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230321005145\/en\/1742539\/21\/Neurent_Medical_Logo.jpg\"><\/a><\/p>\n<p>\nApproximately one in four Americans have chronic rhinitis<sup>1<\/sup>, a condition that results in persistent congestion, rhinorrhea (runny nose), sneezing, and nasal itching caused by inflammation and swelling of the mucosal membrane in the nose. NEUROMARK\u2019s unique device and intelligent technology platform enable otolaryngologists to treat chronic rhinitis with precision and control, which in turn allows for an enhanced patient experience from treatment through recovery.\n<\/p>\n<p>\nThe CLARITY Study enrolled thirty-six participants and all completed follow-ups at one and three months. Primary endpoints were device-related serious adverse events (SAEs) at 1 month and change from baseline in visual analog scale nasal symptom scale (VAS NSS) for rhinorrhea and nasal congestion at 3 months. Total Nasal Symptom Score (rTNSS) and mini Rhinoconjunctivitis Quality of Life Questionnaire (mini RQLQ) score were also evaluated.\n<\/p>\n<p>\nThe data demonstrated the following benefits of NEUROMARK\u2019s posterior nasal nerve (PNN) ablation procedure at 3 months post procedure:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThe mean VAS NSS scores for rhinorrhea and nasal congestion significantly improved from baseline (both <i>p<\/i>&lt;0.0001), achieving a mean percent change of 53% and 55%, respectively.\n<\/li>\n<li>\nTotal rTNSS scores and all individual items demonstrated significant improvement (all <i>p<\/i>&lt;0.001).\n<\/li>\n<li>\nPercent responder rate (\u226530% reduction from baseline in total rTNSS) was 78%.\n<\/li>\n<li>\nTotal mean mini RQLQ scores and all subdomains improved significantly (<i>p<\/i>&lt;0.0001).\n<\/li>\n<li>\n89% of participants reported a minimal clinically important difference (MCID) of \u22650.4 point improvement in the mini RQLQ score.\n<\/li>\n<li>\nNo serious adverse events occurred during the study, and there were no reports of epistaxis or headaches.\n<\/li>\n<\/ul>\n<p>\n\u201cPeople living with chronic rhinitis have had limited options when traditional therapies fail. Other therapies on the market don\u2019t always adequately address symptoms for every patient,\u201d said Douglas D. Reh, MD, FARS, Otolaryngology Specialist at ENT Associates and the study\u2019s principal investigator. \u201cThe data showed statistically significant and clinically meaningful improvement in symptoms and quality of life assessments at 3 months post NEUROMARK procedure.\u201d\n<\/p>\n<p>\nNEUROMARK is designed to gently apply controlled low-power radio frequency (RF) energy to target regions of the nasal cavity, disrupting the parasympathetic nerve signals that can trigger an inflammatory response. This unique system offers ENTs a novel and unique leaflet design to help deliver precision neurolysis of posterior nasal nerves, with the intelligence and flexibility to comfortably accommodate a range of anatomies.\n<\/p>\n<p>\n\u201cWe\u2019re encouraged by the three-month CLARITY data demonstrating the safety, efficacy and relief from chronic rhinitis symptoms that can be achieved with NEUROMARK,\u201d said Neurent Medical CEO Brian Shields. \u201cI\u2019m grateful to Dr. Reh and each of the study\u2019s investigators for adding to the growing body of clinical evidence supporting PNN for these patients.\u201d\n<\/p>\n<p>\nThe NEUROMARK System has received <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fneurentmedical.com%2Fneurent-medical-receives-fda-clearance%2F&amp;esheet=53364703&amp;newsitemid=20230321005145&amp;lan=en-US&amp;anchor=U.S.+Food+and+Drug+Administration+%28FDA%29+clearance&amp;index=3&amp;md5=7ad95839a7aa66bc3185933d9e0ccbe3\" rel=\"nofollow noopener\" shape=\"rect\">U.S. Food and Drug Administration (FDA) clearance<\/a> and Neurent Medical announced the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20230203005078%2Fen%2FNeurent-Medical-Announces-Limited-Market-Release-of-NEUROMARK%25C2%25AE-System-to-Treat-Chronic-Rhinitis&amp;esheet=53364703&amp;newsitemid=20230321005145&amp;lan=en-US&amp;anchor=limited+market+release&amp;index=4&amp;md5=2c7f1749b0646827e2816b6454079765\" rel=\"nofollow noopener\" shape=\"rect\">limited market release<\/a> of the system in February 2023.\n<\/p>\n<p>\n<b>About Neurent Medical<\/b>\n<\/p>\n<p>\nNeurent Medical is pioneering innovative treatments for chronic inflammatory sinonasal diseases by targeting and safely disrupting hyperactive autonomic nerves that drive underlying inflammation. Its proprietary NEUROMARK\u00ae technology with a unique design and advanced algorithmic control, physicians can precisely target and safely disrupt multiple underlying nerve branches in a single procedure to alleviate Chronic Rhinitis symptoms and improve patient quality of life. The venture capital-backed company is headquartered in Galway, Ireland. For more information visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.neurentmedical.com&amp;esheet=53364703&amp;newsitemid=20230321005145&amp;lan=en-US&amp;anchor=www.neurentmedical.com&amp;index=5&amp;md5=e775b624b760b5340206e9efad4d360d\" rel=\"nofollow noopener\" shape=\"rect\">www.neurentmedical.com<\/a>.\n<\/p>\n<p>\n<sup>1 <\/sup>Settipane RA, Charnock DR. Epidemiology of rhinitis: allergic and nonallergic. Clin Allergy Immunol. 2007;19:23-34. PMID: 17153005.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nHealth+Commerce<br \/>\n<br \/>Angela Christoforos<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#97;&#x69;&#x6c;&#116;&#111;&#x3a;&#x61;&#110;&#103;&#x65;&#x6c;&#97;&#64;&#x68;&#x65;&#97;&#108;&#x74;&#x68;&#97;&#110;&#x64;&#x63;&#111;&#109;&#x6d;&#x65;&#114;&#99;&#x65;&#x2e;&#99;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x61;&#110;&#x67;&#x65;&#108;&#x61;&#64;h&#x65;&#97;l&#x74;&#104;a&#x6e;&#100;c&#x6f;&#109;&#x6d;&#x65;&#114;&#x63;&#x65;&#46;&#x63;&#111;m<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Results from the CLARITY Study Show the NEUROMARK\u00ae System Provides Safe and Effective Treatment for Patients with Chronic Rhinitis GALWAY, Ireland&#8211;(BUSINESS WIRE)&#8211;Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, today announced three-month data from the CLARITY study, a prospective, single-arm, multicenter safety and efficacy study of its NEUROMARK\u00ae System &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55021","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New Data show NEUROMARK\u00ae Chronic Rhinitis Treatment Offers Significant Symptom Improvements - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Data show NEUROMARK\u00ae Chronic Rhinitis Treatment Offers Significant Symptom Improvements - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Results from the CLARITY Study Show the NEUROMARK\u00ae System Provides Safe and Effective Treatment for Patients with Chronic Rhinitis GALWAY, Ireland&#8211;(BUSINESS WIRE)&#8211;Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, today announced three-month data from the CLARITY study, a prospective, single-arm, multicenter safety and efficacy study of its NEUROMARK\u00ae System ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-21T11:05:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230321005145\/en\/1742539\/21\/Neurent_Medical_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"New Data show NEUROMARK\u00ae Chronic Rhinitis Treatment Offers Significant Symptom Improvements\",\"datePublished\":\"2023-03-21T11:05:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\\\/\"},\"wordCount\":652,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230321005145\\\/en\\\/1742539\\\/21\\\/Neurent_Medical_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\\\/\",\"name\":\"New Data show NEUROMARK\u00ae Chronic Rhinitis Treatment Offers Significant Symptom Improvements - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230321005145\\\/en\\\/1742539\\\/21\\\/Neurent_Medical_Logo.jpg\",\"datePublished\":\"2023-03-21T11:05:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230321005145\\\/en\\\/1742539\\\/21\\\/Neurent_Medical_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230321005145\\\/en\\\/1742539\\\/21\\\/Neurent_Medical_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Data show NEUROMARK\u00ae Chronic Rhinitis Treatment Offers Significant Symptom Improvements\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Data show NEUROMARK\u00ae Chronic Rhinitis Treatment Offers Significant Symptom Improvements - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\/","og_locale":"en_US","og_type":"article","og_title":"New Data show NEUROMARK\u00ae Chronic Rhinitis Treatment Offers Significant Symptom Improvements - Pharma Trend","og_description":"Results from the CLARITY Study Show the NEUROMARK\u00ae System Provides Safe and Effective Treatment for Patients with Chronic Rhinitis GALWAY, Ireland&#8211;(BUSINESS WIRE)&#8211;Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, today announced three-month data from the CLARITY study, a prospective, single-arm, multicenter safety and efficacy study of its NEUROMARK\u00ae System ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-21T11:05:12+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230321005145\/en\/1742539\/21\/Neurent_Medical_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"New Data show NEUROMARK\u00ae Chronic Rhinitis Treatment Offers Significant Symptom Improvements","datePublished":"2023-03-21T11:05:12+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\/"},"wordCount":652,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230321005145\/en\/1742539\/21\/Neurent_Medical_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\/","url":"https:\/\/pharma-trend.com\/en\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\/","name":"New Data show NEUROMARK\u00ae Chronic Rhinitis Treatment Offers Significant Symptom Improvements - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230321005145\/en\/1742539\/21\/Neurent_Medical_Logo.jpg","datePublished":"2023-03-21T11:05:12+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230321005145\/en\/1742539\/21\/Neurent_Medical_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230321005145\/en\/1742539\/21\/Neurent_Medical_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/new-data-show-neuromark-chronic-rhinitis-treatment-offers-significant-symptom-improvements\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"New Data show NEUROMARK\u00ae Chronic Rhinitis Treatment Offers Significant Symptom Improvements"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55021","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55021"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55021\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55021"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55021"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55021"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}